Treatment for Arthrosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Arthrosis
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is to compare the results of the Medacta GMK Sphere® knee to the Posterior Stabilized knee at the two and five year time points.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Baseline, 2 and 5 year time points

Year 5
Evaluate the change in Forgotten Knee Scores (FJS) of those patients receiving the Medacta GMK Sphere from baseline to years 2 and 5 post-operatively.
Pre-operative and 6 weeks
AP long standing X-ray
Year 5
Krackow Activity Scale (KAS)
Radiographic Analysis
Year 5
Total Knee Society Score (KSS)

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

260 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 2 and 5 year time points

Who is running the clinical trial?

Medacta USALead Sponsor
14 Previous Clinical Trials
2,004 Total Patients Enrolled
Mukesh Ahuja, MBBS, MSStudy DirectorMedacta USA, Inc.
4 Previous Clinical Trials
571 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to comply with follow-up requirements including postoperative weight bearing restrictions and self evaluations.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: October 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.